News and Announcements
Prescient Therapeutics PTX-200 Breast Cancer Trial Progresses
- Published February 18, 2016 10:16AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
17th February 2016, ASX announcement
PTX-200 Breast Cancer Trial Progress
- Phase Ib breast cancer trial enters expansion cohort
- H.Lee Moffitt Cancer Center joins trial recruitment
Melbourne, Australia 17 February 2016: Clinical stage oncology company Prescient Therapeutics Ltd (PTX) is pleased to announce that the last patient (patient 17) has been dosed in the escalation stage of its Akt inhibition Phase Ib breast cancer trial at Montefiore Cancer Center of Albert Einstein University in New York (Albert Einstein University) under the guidance of Professor Joseph Sparano. The trial is targeting women with metastatic and locally advanced HER2 negative breast cancer.
This latest patient received treatment on the third dose level and had no dose limiting toxicity (DLT). As a result, the recommended Phase II dose (RPTD) for this trial has been determined as 35 mg/m2 PTX-200, together with chemotherapy.
As part of this expansion stage, PTX is pleased to announce that the H.Lee Moffitt Cancer Center (Moffitt) in Tampa, Florida will shortly join Albert Einstein University in the Phase Ib expansion cohort and the Phase II trial, and is expected to soon commence recruitment.
Dr. Heather Han, a medical oncologist specializing in breast cancer in the Center for Women’s Oncology at Moffitt, will conduct the study.
To read the full announcement, please click here.
Company Updates
How Capital HQ Slashes Capital Raising Time by 80% for Founders
For startup founders, the capital raise process can feel like a relentless, time-consuming marathon, often diverting precious energy from the core business. “I remember finishing a capital raise at one stage and I remember spending about three months on it and for the money was brought in I thought that money could have been generated […]
The Great Convergence: The $19 Trillion Shift Defining the Next Era of Wealth
A quiet but powerful trend is re-architecting global finance: the great convergence of traditional finance and digital assets. With Boston Consulting Group forecasting the tokenized real-world assets market to hit $16 trillion by 2030, this isn’t speculation—it’s a new institutional reality. Discover the infrastructure being built, the power of tokenization, and how mature DeFi strategies are defining the next era of wealth.
Beyond the Grandstand: Why Australian Sport is the New Asset Class for Family Offices
Australian sport is evolving into a compelling, institutional-grade asset class. Driven by a “golden decade” of major events and significant private capital, it offers high-growth, uncorrelated returns, making it an attractive new frontier for savvy family offices.
Backed By Leading Investment Groups and Family Offices
